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SUMMARY  53 
Infections during pregnancy that may cause congenital abnormalities have been recognized 54 
for decades, but their diagnosis is notoriously challenging. This was recently again illustrated 55 
with the emergence of Zika virus (ZIKV), highlighting the inherent difficulties in estimating 56 
the extent of pre- and postnatal ZIKV complications, because of the difficulties in establishing 57 
definitive diagnoses. We reviewed the epidemiology, infection kinetics and diagnostic 58 
methods used in Toxoplasma gondii, Parvovirus B19, Rubella virus and Cytomegalovirus 59 
(TORCH) infections and compared that with current knowledge of ZIKV diagnostics to 60 
provide a basis for the inclusion of ZIKV in the TORCH complex evaluations.  61 
Similarities between TORCH pathogens and ZIKV support inclusion of ZIKV as an emerging 62 
TORCH infection. Our review evaluates diagnostic performance for maternal screening, fetal 63 
screening and neonatal screening. We show that sensitivity, specificity, and positive and 64 
negative predictive value of TORCH complex pathogens are wide widely variable, stressing 65 
the importance of confirmatory testing and the need for novel techniques for earlier and more 66 
accurate diagnosis of maternal and congenital infections. In this context it is also important to 67 
acknowledge different needs and access to care for different geographic and resource settings.  68 
 69 
INTRODUCTION  70 
The present Zika virus (ZIKV) epidemic was first noted through an alert from the Brazilian 71 
health authorities notifying the World Health Organization (WHO) of an illness characterized 72 
by skin rash in north-eastern states and subsequently signalling an almost 20-fold increase in 73 
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the incidence of microcephaly in newborns coinciding with rapid spread of ZIKV after 74 
incursion into the continent [1,2,3,4]. Until then, ZIKV infection was generally assumed to be 75 
associated with mild and transient disease, estimated to be asymptomatic in approximately 76 
80% of the cases [5]. Hence, it is likely that the infection is underdiagnosed or underreported 77 
in a disease-endemic setting [6]. 78 
The association of ZIKV infection with congenital neurological disease has since then been 79 
subject of numerous publications. First establishment of ZIKV causal association with 80 
neuropathological processes came from a study showing widespread ZIKV infection in the 81 
brain of a fetus from a pregnancy that had been terminated due to severe fetal malformation 82 
[7]. Further evidence for the association came from larger case series, retrospective analysis 83 
of notification data from regions with prior outbreaks [8], and replication of the syndrome in 84 
animal models [9,10,11,12,13]. Although there is general agreement of such association, 85 
many uncertainties remain with regard to actual risk of fetal infection during pregnancy [14]. 86 
A systematic review estimated the prevalence of microcephaly at 2.3% (95%CI: 1,0-5.3% 87 
[15], but estimates range widely and little is known about the risk of complications in relation 88 
to timing of maternal infection (first trimester versus later exposures), prior (flavi virus) 89 
exposure, the rate of transplacental transmission in relation to these factors, the rate of fetal 90 
infection, and the rate of congenital disease once infected (Figure 1). Two recent reports 91 
suggest a decreasing risk over the course of pregnancy [16,17].  A recent European study 92 
showed an overall congenital anomaly prevalence of any (non-genetic) cause of 1.5/100 total 93 
births, but for microcephaly interpretation was hampered by differences in diagnostic criteria 94 
[18]. 95 
At present, ZIKV diagnostic algorithms are based on the use of reverse transcriptase-96 
polymerase chain reaction (RT-PCR) for virus detection and/or serological determination of 97 
pathogen-specific IgM and IgG antibodies supplemented with virus neutralisation assays if 98 
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available. All of the assays have benefits but also known limitations, challenging 99 
interpretation at different stages of pregnancy, particularly in relation to the wide diversity of 100 
flavivirus background exposures in the regions where ZIKV circulates. Virus genome 101 
detection by RT-PCR is considered confirmatory but has a very short detection window as 102 
ZIKV viremia is short, although virus may persist for longer periods in other body fluids, with 103 
reported persistence up to 120 days for semen [19]. Also pregnant women may experience 104 
prolonged viremia [20,21], with reported (transient) presence of ZIKV in fetal blood and 105 
amniotic fluid described in a well described small case series [21]. Antibody based testing is 106 
severely hampered by cross-reactivity with antibodies from prior flavivirus exposures.  107 
Other infections during pregnancy are associated with congenital and subsequent neonatal 108 
disease, sometimes referred to as TORCH infections (Toxoplasma gondii (TOXO), Other 109 
[e.g. varicella zoster, parvovirus B19 (PB19)], Rubella (RV), Cytomegalovirus (CMV) and 110 
Herpes simplex (HSV) with or without syphilis [22]. Diagnosis of fetal infection and linking 111 
fetal infections to clinical outcomes requires knowledge of infection kinetics, including timing 112 
and differentiation of primary from nonprimary infection (i.e. re-activation, re-infection), 113 
maternal and fetal immune response in relation to pathology, and availability of biomarkers 114 
predictive of vertical transmission and presence and/or severity of fetal abnormalities 115 
[23,24,25]. For instance, TOXO and CMV cause persistent or latent infections, whereas RV, 116 
PB19 and ZIKV infection are thought to be primarily self-limiting. Immunocompetent 117 
pregnant women with previous infection with TOXO are considered not at risk for congenital 118 
abnormalities, whereas for CMV primary as well as subsequent infections are associated with 119 
congenital infection and abnormalities, albeit with a lower attributable risk.  The recent ZIKV 120 
epidemic and its possible association with microcephaly has initiated the discussion to include 121 
ZIKV as novel TORCH pathogen [26].   122 
 6 
Although the described maternal infections are an important cause of fetal and neonatal 123 
morbidity and mortality, on a global scale, the overall contribution to fetal and congenital 124 
diseases is limited [27,28,29] due to cumulative low and/or limited a priori risks of maternal 125 
infection, vertical transmission and subsequent congenital infection (Figure 1).  126 
Generally, risk of congenital disease following maternal infection is linked to primary 127 
infection and timing in pregnancy infection, which is pathogen dependent 128 
[25,30,31,32,33,34,35,36,37]. Non-primary maternal infections may result in fetal 129 
transmission, but only in the case of CMV does this contribute significantly to congenital 130 
disease [38]. 131 
The low attributive risk of TORCH and ZIKV infections to congenital disease has 132 
consequences for diagnostic accuracy and the ability to provide information relevant for 133 
clinical decision-making. This is further complicated by the high proportion of asymptomatic 134 
maternal infections [6,35,39,40,41], challenging timely detection of fetal infection and early 135 
neonatal congenital disease, which may remain asymptomatic for years  [40,42].  Early 136 
diagnosis of fetal disease risk in pregnancy, however, is important particularly when early 137 
therapeutic management is available eg. in TOXO [43]. Consequently, diagnostic algorithms 138 
should reliably and timely detect maternal infection, determine (risk of) vertical transmission 139 
and establish or exclude congenital infection. This review assesses diagnostic methods 140 
presently used for TORCH infections, their correlation with congenital and/or neonatal 141 
disease, their predictive value in prenatal screening; it will document gaps in methods used; 142 
and it will draw implications for diagnostic algorithms d evelopment in novel or (re)emerging 143 
infections such as Zika virus.  144 
 145 
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EPIDEMIOLOGY, INFECTION AND TRANSMISSION RISKS OF SELECTED 146 
TORCH PATHOGENS (FIGURE 1) 147 
The risk of infection during pregnancy varies by pathogen and depends upon geographic 148 
region, prevalence in the population, and preventative (vaccination) practices.   149 
The seroprevalence of Toxoplasma gondii among women of childbearing age shows a broad 150 
range, from   <2% in a large Chinese cohort [44] up to 75% in Brazil [45], with a mean 151 
estimate of around 40% [46,47,48]. Similar broad ranges in seroprevalence between 30-72% 152 
are reported for PB19 and CMV [49,50,51,52,53,54,55,56] although for CMV 153 
seroprevalences up to 100% are also reported [57]. RV seroprevalence estimates depend on 154 
(differences in) vaccination practices [58,59,60].  ZIKV seroprevalence has a geographic 155 
distribution, varying from <2% in travellers returning from endemic areas or blooddonors in 156 
non-endemic settings [61,62,63] to up to 39% in healthy individuals living in endemic areas 157 
[64,65] increasing to >60% following outbreaks [66, 67]. These wide ranges in background 158 
seroprevalence affect the likelihood of primary infection during pregnancy, as well as the 159 
interpretation of diagnostic assays, and need to be taken into account when developing 160 
diagnostic algorithms.  161 
 162 
To assess clinical impact of exposure to TORCH pathogens and ZIKA during pregnancy, it is 163 
important to consider maternal infection risk, fetal transmission risk, and congenital infection 164 
risk for each pathogen (Figure 1). Maternal infection risk (MIR) estimates defined as the 165 
annual infection rate for selected TORCH infections, range from 0.1-0.6% for TOXO [31] to 166 
2-7% for PB19 and CMV [68,69,70,71,72,73], with epidemic rise up to 10% in PB19. 167 
Reliable data for RV MIR is lacking in an elimination setting, but annual incidence is 168 
estimated at 1.3/100.000 pregnancies in the general population [74]. A 6.4% IgG 169 
seroconversion was reported in women with non-immune RV titers prior to pregnancy [75].  170 
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Although efforts have been made to calculate the maternal infection risk for ZIKV, reliable 171 
data are still lacking, due to several factors including diagnostic limitations (e.g. cross-172 
reactivity) [76,77], and difference and rapid changes in epidemiology.  173 
Fetal transmission risk (FTR), defined as the proportion transplacental transmission following 174 
(primary) infection during pregnancy, is also pathogen dependent and is linked to timing of 175 
infection during pregnancy. FTR may increase (TOXO, PB19, CMV) or decrease (RV) 176 
during the pregnancy period, with a variable mean FTR estimated to range from 24-80% for 177 
these pathogens [25,33,42,78,79]. For ZIKV, FTR is thought to be highest during first 178 
trimester, but more data is needed [16,17]. Perinatal transmission has also been reported for 179 
ZIKV [80].  180 
Despite high FTR, the congenital infection risk (CIR) defined as number of congenital 181 
infections per 1000 live births (or number of fetal deaths/hydrops fetalis per 1000 infeced 182 
fetuses in PB19) is low, ranging from <1/100000 pregancies (RV) up to 0,1-20/1000 183 
pregnancies in TOXO, PB19 and CMV [33,34,81,82,83,84,85,86,87,88,89].  Overall 184 
congenital CMV infection is most prevalent in the developed world (5-20/1000 live births) 185 
[30,90], followed by toxoplasmosis (0.1-5/1000 live births) [31,46], and RV (annual 186 
incidence 0.4/100.000)[81].  Parvovirus B19 is associated with hydrops fetalis [82,83,84] and 187 
fetal death, with an estimated annual incidence of <4/1000 fetuses [85].  Recent studies 188 
estimated the contribution of symptomatic ZIKV during pregnancy to ZIKV associated 189 
congenital disease at 7% [17], and evidence of acute infection in pregnancy at less then 4% 190 
[77].  How this translates to the overall contribution of ZIKV to e.g. congenital microcephaly 191 
prevalence depends on the baseline risk and these are uncertain [18,91]. A retrospective 192 
analysis in French Polynesia estimated a risk of microcephaly associated with ZIKV infection 193 
at 9.5/1000 pregnancies, with an overall risk of microcephaly in 0.2/1000 neonates [8]. 194 
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CIR does not necessarily follow the FTR, with highest CIR in the 1st trimester for TOXO, RV 195 
and CMV [25,35,34,42] and highest CIR in the second trimester for PB19 [36,37]. Also, for 196 
ZIKV highest risk is reported in 1st trimester [8,17]. Overall CIR is limited to primary 197 
infection, except for CMV, where re-infection or re-activation contributes mainly to 198 
congenital CMV disease burden [56,92]. Latent or chronic TOXO infection does not exclude 199 
transmission but does not result in CIR in non-immunocompromised pregnancies [93,94]. In 200 
general, the low attributive risk of the reported infections to overall prevalence of congenital 201 
disease [27,28,29] impacts on the performance of diagnostic assays.   202 
This implies that the low a priori attributive risk of TORCH and ZIKV to congenital 203 
infections needs to be included in every step excluding or confirming maternal, fetal and/or 204 
congenital infection. 205 
  206 
MATERNAL DIAGNOSTIC TESTING (FIGURES 2A – 2D) 207 
Infection kinetics 208 
Interpretation of diagnostic testing during pregnancy requires knowledge on infection kinetics 209 
defined by prevalence and duration of symptoms, duration of pathogen presence in different 210 
body fluids, loads, timing of development of specific antibodies, background antibody 211 
prevalence, and relationship between these parameters.  Molecular detection in early 212 
symptomatic infection is generally considered proof of acute primary infection [17,40,59,95], 213 
although not true for each pathogen, i.e. CMV.  Primary infections typically show IgM and 214 
IgG development, determined with serological assays with or without confirmatory testing 215 
[96,97].  Reported antibody kinetics differ between selected pathogens.  TOXO IgM 216 
seroconversion occurs relatively late between 15-30 days [98,99],  whilst early IgM rise is 217 
observed for PB19 towards the end of the first week of infection coinciding with peak viremia  218 
[56] as well as for RV whose IgM rise within 5 days after rash onset [100].  CMV IgM may 219 
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become detectable between 0-3 weeks [101] with peak IgM observed between 1-3 months 220 
[102]. IgM antibodies against ZIKV also show an early rise and can be first detected within 221 
the first week after clinical symptoms, but also IgG antibodies can be detected within the first 222 
two weeks [103].  223 
PB19 IgM can persist up to 3 months postinfection [104], and ZIKV IgM can also persist 224 
beyond 3 months with a reported wide range [105]. In addition, long-term persistence of 225 
rubella IgM is reported following vaccination [106,107,108], due to natural occurrence of 226 
non-specific IgM [109,110] and despite attempts to improve assays [111,112,113,114]. 227 
Differentiation of acute infection from latent infection or re-activation / re-infection is 228 
important in TOXO and CMV, as IgM/IgG may coincide thereby making it difficult to 229 
diagnose primary infection if first consultation yields an IgM/IgG positive test result [115]. In 230 
this case, confirmatory testing is needed, e.g., by AI or IB with presently available assays.  231 
[47,116,117]. Development of CMV specific IgG with a negative sample collected earlier in 232 
pregnancy is considered proof of primary CMV infection, although in absence of routine 233 
screening this is usually not feasible [118]. 234 
 235 
Molecular assay performance and limitations 236 
Although PCR assay specificity is high in acute primary infection, the window of PCR 237 
positivity may be short as shown for PB19 [95] [Figure 2].  Limited data from ZIKV showed 238 
a similar pattern. A recent external quality assessment (EQA) suggested similar more robust 239 
specificity and variable sensitivity between labs [119].  Furthermore, most acute (primary) 240 
infections in pregnancy are asymptomatic, and day of infection is unknown precluding use of 241 
this gold standard test. In primary PB19 in pregnancy, high viral load in acute infection is 242 
associated with early positive IgM [39,56,120,121].  Long-term, low load, DNA (desoxyribo 243 
nucleic acid) persistence is observed following PB19 infection [104,122]. In one study, the 244 
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use of endonuclease treatment before molecular testing differentiated naked DNA persistence 245 
from true viremia [123]. For ZIKV, rapid degradation of RNA (ribo nucleic acid) was 246 
reported in urine samples [124]. In acute maternal PB19 infection, positive predictive value 247 
(PPV) of PB19 PCR is high, but at time of fetal symptoms, the PPV of PB19 DNA detection 248 
in maternal blood is generally low, as clinical symtoms in the fetus are usually observed when 249 
maternal viremia has ceased. This timely relation is not established for other primary 250 
infections such as TOXO [125,126] or CMV [127]. Viremia in pregnant women is associated 251 
with vertical transmission risk and increased CIR but the relationship between maternal 252 
infection, FTR and CIR is different for different pathogens [128,129,130,131,132,133,134]. 253 
Currently, there is no obvious predictor for transmission risk. For instance, viral load does not 254 
differentiate transmitters from non-transmitters in CMV [129,130,135]. Absence of 255 
relationship with maternal disease severity or viral load was also recently described for 256 
congenital ZIKV [136].  Low viral load positives may occasionally not show IgM 257 
seroconversion (RV, ZIKV) [137,138,139], low assay sensitivity was suggested as one of the 258 
possible explanations [139].  Genotype differences may impact sensitivity of assays 259 
[140,141,142] which is important when considering using assays in different regions.  260 
 261 
Serological assays and performance 262 
Primary diagnostic assays  263 
Generally, TORCH immunoassays report relatively high specificity for IgM and IgG or in 264 
IgM negative samples [34,108,113,143) but as the a priori likelihood of a maternal infection 265 
with TORCH pathogens generally is low, even a relatively low false positivity rate translates 266 
to a low PPV for all pathogens (including ZIKV) except PB19, stressing the need for 267 
confirmatory testing [144,145,146,147] [figure 2]. Comparative studies of assays, reporting 268 
relative performance data overestimate sensitivity and specificity [108,113, 143, 148]. In view 269 
 12 
of the above, a positive IgM test result always requires confirmation with other assays 270 
[36,101,113,149] and follow up samples. More specific (recombinant) peptide specific IgM 271 
assays may provide solutions, but their performance also needs to be fully evaluated 272 
[121,150].   273 
 274 
Confirmatory testing 275 
The use of confirmatory testing with avidity index measurements (AI), immunoblots (IB) and 276 
virus neutralisation testing (VNT) is not consistent between pathogens and also show variable 277 
performances (Figure 2).  Testing for AI is common practice for TOXO and CMV 278 
diagnostics, but not for PB19 [121] or RV [151]. The rationale for avidity testing is that 279 
avidity of antibodies increases with time, and high AI correlates with infection in the more 280 
distant past [152,153,154,155,156,157,158]. Confirmatory sensitivity of AI depends upon the 281 
initial screening platform used, as shown in one study. A negative initial IgM screening is 282 
unlikely to be confirmed [145]. IgM positivity combined with low AI increases sensitivity and 283 
PPV of the combined assays in diagnosing recent infection [159,160,161,162].  In contrast 284 
(persistent) low AI with positive IgG has a relatively high negative predictive value (NPV) 285 
[163,164]. High AI plus IgG usually confirms past infection, however, for TOXO AI 286 
maturation may never occur [165]. Rapid increase in AI in CMV was associated with false 287 
exclusion of recent infection [166] with higher FTR [167] and CIR [168]. Therefore, 288 
exclusion of acute infection based on (high) AI requires a predefined time window 289 
[101,114,169,170,171], and size of the window varies depending on pathogen, thresholds and 290 
platforms [172]. Different antigens, including recombinant antigens as target for antibody 291 
response may improve AI assay performance [170].   292 
Antibody test results may also be confirmed by IB [101,173] or different complementary 293 
assays [174]. Epitope-specific IgG IB used in TOXO and PB19 could confirm IgM/IgG 294 
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measurements [175,176] particularly in equivocal outcomes [177] or in (false) negative 295 
results with high viral load [146] and helped timing of infection by correlation of IB with 296 
virusneutralisation in CMV [178] or with AI in TOXO [179].  297 
An interesting application is the use of IB in TOXO for discrimination of maternal and 298 
neonatal antibody responses by comparing patterns of antibody binding to different proteins 299 
or peptides in blood from mother and neonate [180]. Limitations of IB include lack of 300 
standardisation with variable concordance between assays, particularly in acute infection 301 
[181,182] and different diagnostic accuracy of band patterns in the blots [175]. Predictive 302 
value of IB depends upon the target, and IgM blots often have poorer predictive value 303 
compared to IgG blots [173,183].  Virusneutralisation data are primarily available for CMV 304 
[96], but also commonly used in confirmation of ZIKV infection [184], with generally high 305 
assay performance.  306 
 307 
Limitiations of serodiagnostic assays 308 
A major limitation for all diagnostic methods described is interassay variability [98,185], use 309 
of different cut-offs, differences in classifications of positives [185,186], low agreement 310 
between AI index assays [187],  variability between platforms 311 
[165,114,171,172,188,189,190,191] and lack of standardization. Another serious concern is 312 
the “grey zone” classification, i.e. the area  between the negative outcome and the positive 313 
outcome of a test  [98,114,153,163,164,166,186,187,192,193], which differs considerably 314 
between assays [194] and the lack of standardisation of cut-off values for the same assay 315 
[183]. Assigning the grey zone to the negative or positive group impacts on sensitivity or 316 
specificity (as indicated in figure 2, where for example category Tox+ denotes the assignment 317 
of grey zone to the seropositive group and Tox – assignment to the seronegative group) 318 
[148,195,196] stressing the need for common standards  for assay development and validation 319 
 14 
[197,198,199,200,201], use of a standardcurve [202] and/or (international) standardization  as 320 
shown in RV [186,203]. Even when general standards for defining seropositivity are applied, 321 
different assays show different performance characteristics which is impacted by the 322 
assignment of equivocal results to the positive or negative outcome [108,204,205]. Since this 323 
mainly affects sensitivity it increases NPV, particularly when prevalence decreases 324 
[92,168,206,207,208]. 325 
 326 
FETAL INFECTION DIAGNOSTIC TESTING (FIGURES 3A – 3D)  327 
In case of suspected fetal infection, molecular detection of virus DNA or RNA in amniotic 328 
fluid (AF) or cordblood (CB) is the primary diagnostic option in most cases except in TOXO. 329 
Limited serological data on AF include IgM determination [209,210]. IgG determination is 330 
not informative as it is usually of maternal origin.  IgM and/or IgA determination in AF or 331 
fetal blood (FB) have low diagnostic value [211,212,213,214,215], whereas cell culture 332 
isolation (virological confirmation) is more specific for example in CMV [215]. Loads in FB 333 
or AF may be 100-1000-fold higher than in maternal blood [157,129,216], particularly in 334 
symptomatic fetuses [217,218,219] as shown in PB19, CMV and TOXO. Although (viral) 335 
load in primary infection may be high in the fetus [211] its presence is not necessarily 336 
associated with symptomatic infection [220,221,222,223]. Also, normal pregnancy outcome 337 
has been observed in maternal seroconversion without positive AF-PCR [208]. These 338 
discrepancies possibly reflect different windows of infection detection. Overall when 339 
available, PCR on AF or FB has good specificity and NPV in the fetus (Figure 3) 340 
[210,224,225,226,227,228,229] . For PB19, sensitivity has been shown to increase in 341 
presence of maternal viremia [216], and for TOXO with a shorter interval to AF or FB 342 
sampling [224, 226] or use of multicopy genes [230]. Assay performance may be different 343 
between AF and FB, with reported concordance between 73% and 99% [210,213]. Although 344 
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(transient) ZIKV was reported in AF and FB in fetuses of women with proven infection 345 
during pregnancy [21],  there are no quantitative data on FB/AF in Zika available at this point 346 
[231]. 347 
 348 
POSTPARTUM DIAGNOSTIC TESTING (FIGURES 4A – 4D) 349 
Postpartum sequelae of fetal infections have been observed for TOXO, RV, CMV and ZIKV. 350 
Although literature is not consistent on this issue, fetal anemia following PB19 infection may 351 
result in severe postpartum sequelae [232]. In general, timely postpartum diagnosis is 352 
hampered by low sensitivity of IgM testing [33,36,40,205,228,233,234,235], the presence of 353 
maternal antibodies, and the high proportion of asymptomatic CMV or TOXO infected 354 
newborns [31,128,224,228,236], unlike for RV [237]. As a consequence, ascertainment of 355 
congenital disease typically requires longer-term follow up, posing challenges to the 356 
differentiation with postpartum infection [40,238,239].  357 
IgM positivity in cord blood or peripheral blood in newborns <24 hours in RV and CMV 358 
confirms prenatal infection when supported by viral load testing [233,240].  IgM assay 359 
performance is better when testing is done more selectively, in symptomatic neonates as 360 
reported for TOXO [218]. Contamination with maternal blood should be excluded within the 361 
first 10 days postpartum if first sample was taken from CB, as shown for TOXO[35].   362 
The majority of IgG detected at birth will be from maternal origin [31,241], but may be 363 
neonatal [242]. Generally maternal IgG is assumed to persist for less than 6 months 364 
[243,244], but for example in TOXO persistence of IgG level at 12 months is used to confirm 365 
or exclude congenital toxoplasmosis and IgG immunoblot is used to overcome the uncertainty 366 
about IgG origin [205,245].  Use of immunoblot or other multi-antigen assays early 367 
postpartum [249] has shown to provide an opportunity to differentiate congenital from non-368 
congenital infection by comparing maternal and neonatal antibody binding patterns [246,247]. 369 
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The feasibility of using differences in AI for this purpose has also been studied, e.g.  for 370 
TOXO and CMV [247,248,249,250]. Slow IgG AI maturation in neonates, in combination 371 
with IgM correlated with congenital RV [251,252], identical neonatal and maternal AI 372 
excluded congenital toxoplasmosis [35].  373 
Molecular testing of neonatal blood or urine has generally good specificity [239,253] with 374 
higher viral load, and longer RNA/DNA persistence in symptomatic babies, particularly in 375 
urine or throat samples for selected pathogens within a selected time frame after birth. 376 
[239,254,255,256]. Viral load has been used to differentiate congenital from postpartum 377 
infection, when early samples are available, but it is not clear if these findings can be 378 
generalized [257].  379 
 380 
EFFORTS AT IMPROVING DIAGNOSTIC ACCURACY  381 
There have been many efforts to improve diagnostic accuracy, however, this has not yet 382 
resulted in significant improvements. These efforts include development of recombinant 383 
(multi-) proteins and peptide specific tests using different techniques (e.g., 384 
immunoproteomics) [258] in (multiplex) assays to improve sensitivity and specificity 385 
[143,259,260,261], distinction between primary and postprimary infection [262,263,264], 386 
timing [265], and transmitters [266]. For example, recombinant proteins in novel avidity 387 
assays reported a PPV of >85% [267] and were better suited for IgG detection in TOXO [268] 388 
or could serve as proxies for functional antibody measurements like virus neutralisation in RV 389 
[269].  Multiplex assays are used for simultaneous detection of different antibodies in 390 
TORCH [34,108,113,143] , which is important for differential diagnostic approaches. 391 
However, assays still have the performance limitations of the standard assays described.  392 
Microarray based assays are developed to improve simulatenous testing of antibodies of 393 
different pathogens, including (extended) TORCH [270].  Use of dry blood spots in multiplex 394 
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serological assays allows use of small volumes, and shorter diagnostic delay [271,272,273], 395 
with potential better assay performance on for example plasmonic gold chip multiplex 396 
immunoassay platforms as shown in TOXO [274,275,276].  Cell mediated immunity (CMI) 397 
assay data (IGRA, ELIspot) particularly come from CMV but is not routinely used. Higher 398 
CD4+/CD8 proliferative T-cell response was associated with primary infection 399 
[277,278,279,280,281], improving assay sensitivity of low IgG avidity [282], but also 400 
reporting different assay performances for example in primary infection and transmitters 401 
[283].  Since CMI in the neonate is never from maternal origin, it is hypothesized that it might 402 
aid in differentiating maternal from foetal ZIKV infection. 403 
Rapid point of care testing, such as immunochromatography [98], loop-mediated isothermal 404 
amplification  (LAMP) [141,284] or digital microfluidic (DMF) diagnostic platforms [285] 405 
studied for different pathogens, may further reduce time to first positive test, increase 406 
sensitivity and/or decentralised availability in resource limited settings.  Such developments 407 
are also reported for ZIKV [286,287, 288,289] Alternative, novel methods in amniotic fluid 408 
samples include comparisons of metabolic profiles (metabolomics) of transmitter vs non-409 
transmitter infections [290,291], cytokine profiles [292] or peptidome prognostic classifiers 410 
[229] to differentiate infected from non-infected fetuses, or distuinguish symptomatic from 411 
asymptomatic infections postpartum.  Such developments are particulary important as they 412 
may provide early (prenatal) information on the risk of overt clinical congenital disease 413 
postpartum..  Other non-pathogen related methods are those comparing differential gene or 414 
protein expression between fetal cells and maternal cells [293].  In analogy with previously 415 
developed tests for non-infectious prenatal screening [294,295], genes associated with 416 
neurodevelopment were studied as biomarkers in cell-free RNA transcripts in AF samples 417 
[296]. Paper-based cell-free RNA was recently evaluated for rapid point of care testing of 418 
ZIKV [297]. 419 
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 420 
CONCLUSIONS 421 
Our review of approaches to diagnose acute maternal infection, determine vertical 422 
transmission risk and establish presence or absence of congenital infection has shown 423 
similarities but also large variation in approaches between pathogens, risking under-424 
exploration of methods for optimal diagnostics. Present diagnosis of TORCH and ZIKV 425 
infections is primarily based on serological testing with a focus on IgM and/or IgG detection, 426 
for which a variety of commercial assays is available. These assays show variable 427 
performance and may not differentiate between primary and non-primary infections [115], 428 
persistence or may be limited by cross reactivity [108,112]. A positive serological test thus 429 
always requires confirmatory testing, including IgG avidity index determinations, 430 
immunoblots, virus neutralisation and molecular testing [43,212,224].   431 
Use of different assays and lack of (international) standardization hamper the interpretation of 432 
and agreement between different studies [298], despite availability of (WHO) recommended 433 
antigens, primers and probes [299]. Efforts to improve detection of primary infection and 434 
timing in pregnancy have not yet resulted in reliable biomarkers for fetal or congenital disease 435 
risk [300]. Even if protocols and/or algorithms are in place, variability between assays 436 
interferes with unambiguous and timely decision making [301].  437 
Thus predefined (more) generic approaches with standardized diagnostic assays and 438 
algorithms are needed to improve adequate and timely diagnosis of (primary) maternal 439 
infections, and subsequent postpartum congenital disease [302], particularly in low endemic 440 
settings where suboptimal diagnostic performance may have an increased risk of false 441 
positive outcomes. Lessons to draw from this review for novel challenges such as ZIKV are to 442 
directly combine methods [52], increase epitope specificity (e.g., avidity, immunoblot, virus 443 
neutralisation) and implement paired mother-fetus and/or mother-child testing, as was 444 
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recently reported for ZIKV neutralising antibodies [303]. Differences in background exposure 445 
to ZIKV and other flaviviruses will have an (age-dependent) effect on cross-reactivity and 446 
interpretation of protein-driven assays, such as IB or micro-array analysis.  In these instances, 447 
CMI might be explored as alternative method to differentiate maternal from congenital ZIKV 448 
infection. Standardisation of (validated reference) methods is critical in order to compare 449 
different methods and might need (a) reference centre(s) to confirm acute infection. There is a 450 
plethora of studies describing potentially improved diagnostics for the TORCH complex 451 
infections, including ZIKV. Exploration of the broad range of published methods is important 452 
to improve diagnostic algorithms. In the meantime, it is essential to raise awareness among 453 
medical microbiologists and treating physicians about the limitations of the presently applied 454 
tests and algorithms, guiding protocol development for diagnostic testing of (novel) infections 455 
such as ZIKV and optimise diagnostic algorithms, for the different geographic and resource 456 
settings. Given the observed disconnect between the different pathogen specialist fields, we 457 
conclude that there is a clear case to be made for an integrated TORCHeZ diagnostic 458 
challenge. 459 
  460 
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FIGURE LEGENDS  461 
Figure 1:  462 
Seroprevalence, maternal infection risk, fetal transmission risk and congential infection risk 463 
of the following selected infections: TOXO, PB19, Rubella, CMV and ZIKV. 464 
 465 
Legend:  466 
        *  seroprevalence at childbearing age 467 
** IR/yr= maternal annual infection rate 468 
  $ FTR= fetal transmission rate 469 
      CIR = congenital infection rate= number of congenital infections per 1000 live 470 
                 births (TOXO) or per 1000 pregnancies (RV, CMV, PB19, ZIKV)  471 
 472 
Figure 2: Routine maternal diagnostic methods: sensitivity and specificity, PPV, NVP 473 
median point estimate +/- 95% CI   474 
 475 
Legend:  476 
Abbreviations: PPV: positive predictive value, NPV: negative predictive value, 95% CI: 95% 477 
confidence interval   478 
References figure 2:  479 
TOXO (n=28): 48,99,113,134,143,150,153,160,161,162,163,165,170,171,175,177,179, 480 
183,189,195,199,200,201,204,205,209,262,304  481 
PB19 (n=14):29,36,53,79,84, 86,121,146,176,197,211,305,306,307 482 
RV (n=9):59,108,137,149,151,186,204,304,308  483 
CMV (n=24):23,53,92,101,112,128,145,148,155,156,159,166,169,173,178,190,196, 204, 484 
,206,250,265,281, 304,309  485 
ZIKV (n=15):289,310,311,312,313,314,315,184,316,317,318,319,320,321,322  486 
 487 
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Figure 3: Routine fetal diagnostics methods: sensitivity and specificity, PPV, NVP median 488 
point estimate +/- 95% CI 489 
 490 
Legend:  491 
Abbreviations: PPV: positive predictive value, NPV: negative predictive value, 95% CI: 95% 492 
confidence interval   493 
References figure 3:  494 
TOXO (n=13): 33,43,126,154,164,209,212,226,227,228,230,323,324 495 
PB19 (n=5):  79,213,220,222,223 496 
RV (n=1): 323 497 
CMV (n=10): 89,129,169,210,222,223,224,229,277,323  498 
 499 
Figure 4: Routine neonatal screening methods: sensitivity and specificity, PPV, NVP median 500 
point estimate +/- 95% CI   501 
 502 
Legend:  503 
Abbreviations: PPV: positive predictive value, NPV: negative predictive value, 95% CI: 95% 504 
confidence interval   505 
References figure 4:  506 
TOXO (n=9): 174,201,212,228,234,246,248,249,325 507 
PB19 (n=2): 36,85  508 
RV (n=2): 233, 252 509 
CMV (n=11):  102, 115,128,158,159,215,238,250,253,277,326  510 
 511 
  512 
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